Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Director Peter Kolchinsky Sells 368,700 Shares of Stock

Share on StockTwits

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Director Peter Kolchinsky sold 368,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $24.04, for a total transaction of $8,863,548.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Peter Kolchinsky also recently made the following trade(s):

  • On Monday, December 2nd, Peter Kolchinsky sold 137,176 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $24.98, for a total transaction of $3,426,656.48.
  • On Friday, November 29th, Peter Kolchinsky sold 138,000 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $24.22, for a total transaction of $3,342,360.00.
  • On Monday, November 25th, Peter Kolchinsky sold 361,200 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $24.06, for a total transaction of $8,690,472.00.
  • On Thursday, November 21st, Peter Kolchinsky sold 351,505 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $22.98, for a total transaction of $8,077,584.90.
  • On Tuesday, November 19th, Peter Kolchinsky sold 397,183 shares of Dicerna Pharmaceuticals stock. The stock was sold at an average price of $23.92, for a total transaction of $9,500,617.36.

DRNA stock opened at $26.48 on Tuesday. Dicerna Pharmaceuticals Inc has a 12-month low of $9.31 and a 12-month high of $26.69. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -22.07 and a beta of 2.38. The company has a 50 day moving average of $18.93 and a two-hundred day moving average of $15.30.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.15). Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. The company had revenue of $8.04 million during the quarter, compared to analysts’ expectations of $11.70 million. As a group, analysts expect that Dicerna Pharmaceuticals Inc will post -1.28 EPS for the current fiscal year.

A number of research firms recently commented on DRNA. BidaskClub raised shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 9th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price (up previously from $22.00) on shares of Dicerna Pharmaceuticals in a research report on Tuesday, November 19th. Robert W. Baird increased their target price on shares of Dicerna Pharmaceuticals from $35.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Leerink Swann reiterated an “outperform” rating and issued a $30.00 target price (up previously from $26.00) on shares of Dicerna Pharmaceuticals in a research report on Tuesday, November 19th. Finally, SunTrust Banks increased their target price on shares of Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $27.38.

Hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Dicerna Pharmaceuticals by 52.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,363 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,151 shares in the last quarter. Quantamental Technologies LLC raised its holdings in shares of Dicerna Pharmaceuticals by 94.4% during the 2nd quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,700 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Dicerna Pharmaceuticals during the 2nd quarter valued at $68,000. Athanor Capital LP bought a new position in shares of Dicerna Pharmaceuticals during the 2nd quarter valued at $233,000. Finally, Virtus ETF Advisers LLC bought a new position in shares of Dicerna Pharmaceuticals during the 2nd quarter valued at $285,000. Institutional investors own 84.77% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Story: The Role of a Fiduciary and Individual Investors

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.